The Government of the Maldives announces that Maldives will join 172 countries to participate in the global COVAX Covid-19 vaccine access plan co-led by the World Health Organization (WHO).
COVAX is coordinated by GAVI, CEPI, and WHO is a pooled procurement mechanism for new Covid-19 vaccines that aims to provide participating economies fair and equitable access to vaccines by pooling purchasing power from these nations across a range of candidate vaccines.
The 172 economies comprise 80 higher-income countries that will finance the Covid-19 vaccines from their own national budgets, while the remaining 92 low- and middle-income countries will receive financial support to access the vaccines. And as per the Health Protection Agency (HPA) of the Maldives, Maldives is within the low- and middle-income countries, hence we will be receiving financial support to access the vaccines.
Two of nine candidate vaccines; Moderna and AstraZeneca-Oxford University, in the COVAX portfolio are currently in Phase 3 trials. Phase 3 trials test the vaccine on thousands of people to observe the vaccine’s effectiveness in preventing Covid-19 infection.
The New York Times also listed BioNTech-Pfizer’s vaccine as being tested under combined Phases Two and Three, while four vaccines in China are in Phase 3.
COVAX is coordinated by GAVI, CEPI, and WHO is a pooled procurement mechanism for new Covid-19 vaccines that aims to provide participating economies fair and equitable access to vaccines by pooling purchasing power from these nations across a range of candidate vaccines.
The 172 economies comprise 80 higher-income countries that will finance the Covid-19 vaccines from their own national budgets, while the remaining 92 low- and middle-income countries will receive financial support to access the vaccines. And as per the Health Protection Agency (HPA) of the Maldives, Maldives is within the low- and middle-income countries, hence we will be receiving financial support to access the vaccines.
Two of nine candidate vaccines; Moderna and AstraZeneca-Oxford University, in the COVAX portfolio are currently in Phase 3 trials. Phase 3 trials test the vaccine on thousands of people to observe the vaccine’s effectiveness in preventing Covid-19 infection.
The New York Times also listed BioNTech-Pfizer’s vaccine as being tested under combined Phases Two and Three, while four vaccines in China are in Phase 3.
